| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the die has not been cast
|
Tomasik, B.
|
|
|
33 |
6 |
p. 658-659
|
artikel
|
| 2 |
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
|
Rugo, H.S.
|
|
|
33 |
6 |
p. 616-627
|
artikel
|
| 3 |
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
|
Fleming, G.F.
|
|
|
33 |
6 |
p. 658
|
artikel
|
| 4 |
Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities
|
Venkataramany, A.S.
|
|
|
33 |
6 |
p. 578-592
|
artikel
|
| 5 |
Classification of atypical EGFR mutations in non-small-cell lung cancer
|
Rosell, R.
|
|
|
33 |
6 |
p. 571-573
|
artikel
|
| 6 |
Clinical trials for metastatic castrate-resistant prostate cancer—who is looking after the control patients? Questions for the future
|
Ardolino, L.C.
|
|
|
33 |
6 |
p. 574-577
|
artikel
|
| 7 |
Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
|
Vogel, A.
|
|
|
33 |
6 |
p. 666
|
artikel
|
| 8 |
Corrigendum to ‘128P Surgical management of lung metastases: A work-in-progress report from an international ESTS research group’ Annals of Oncology Volume 33 Supplement 2 (2022) S91-S92
|
Prisciandaro, E.
|
|
|
33 |
6 |
p. 667
|
artikel
|
| 9 |
Editorial Board
|
|
|
|
33 |
6 |
p. iii
|
artikel
|
| 10 |
Erratum to “Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust”
|
Piccart, M.J.
|
|
|
33 |
6 |
p. 668
|
artikel
|
| 11 |
For ovarian cancer PARPi maintenance therapy: more is better, right?
|
Coleman, R.L.
|
|
|
33 |
6 |
p. 569-570
|
artikel
|
| 12 |
Genetic variation within the human papillomavirus type 16 genome is associated with oropharyngeal cancer prognosis
|
Lang Kuhs, K.A.
|
|
|
33 |
6 |
p. 638-648
|
artikel
|
| 13 |
Improving at a nationwide level the management of patients with sarcomas with an expert network
|
Blay, J.-Y.
|
|
|
33 |
6 |
p. 659-661
|
artikel
|
| 14 |
Inflammatory bowel disease and risk of adenocarcinoma and neuroendocrine tumors in the small bowel
|
Yu, J.
|
|
|
33 |
6 |
p. 649-656
|
artikel
|
| 15 |
Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona
|
Zanelli, S.
|
|
|
33 |
6 |
p. 661-663
|
artikel
|
| 16 |
Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer
|
Okines, A.
|
|
|
33 |
6 |
p. 657-658
|
artikel
|
| 17 |
Table of Contents
|
|
|
|
33 |
6 |
p. i-ii
|
artikel
|
| 18 |
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
|
Francis, K.E.
|
|
|
33 |
6 |
p. 593-601
|
artikel
|
| 19 |
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
|
Janning, M.
|
|
|
33 |
6 |
p. 602-615
|
artikel
|
| 20 |
Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR) ☆
|
Basile, D.
|
|
|
33 |
6 |
p. 628-637
|
artikel
|
| 21 |
VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
|
Moreau, P.
|
|
|
33 |
6 |
p. 664-665
|
artikel
|
Tijdschrift beschrijving